Literature DB >> 2512687

Thrombus age and tissue plasminogen activator mediated thrombolysis in rats.

M Loren1, L J García Frade, M C Torrado, J L Navarro.   

Abstract

Thrombolytic efficacy is directly related to thrombus age. We used recombinant tissue plasminogen activator (rt-PA), Streptokinase (SK) and Urokinase (UK) on a seven days old inferior vena cava thrombus model. "In vitro" clot lysis assays with fibrinogen-I125 were also evaluated with the same agents at 1, 3 and 7 days. Fibrinogen, D-D dimer and t-PA were measured. Experiments with 40 controls and 27 rt-PA treated animals showed a significant decrease in thrombus weight (8.5 +/- 1.1 mg) vs. (4.2 +/- 0.6 mg) (p less than 0.01). Fibrinogen concentration in rt-PA group decreased significantly (1032 +/- 123 mg/dl) vs. (202 +/- 32 mg/dl) (p less than 0.001). "In vitro" rt-PA showed a marked lytic effect in a wide range (100-4 IU/ml). Fibrin selective agents as rt-PA may be more effective than non selective ones in the treatment of fully developed thrombus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2512687     DOI: 10.1016/0049-3848(89)90009-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  13 in total

Review 1.  The management of retinal vein occlusion: is interventional ophthalmology the way forward?

Authors:  H Shahid; P Hossain; W M Amoaku
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

2.  Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.

Authors:  Jason M Meunier; Christy K Holland; Tyrone M Porter; Christopher J Lindsell; George J Shaw
Journal:  Curr Neurovasc Res       Date:  2011-11       Impact factor: 1.990

Review 3.  Intravenous thrombolytics for ischemic stroke.

Authors:  Andrew D Barreto
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

4.  Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.

Authors:  Madhuvanthi A Kandadai; Jason Meunier; Christopher J Lindsell; George J Shaw; Mitchell S V Elkind
Journal:  Curr Neurovasc Res       Date:  2012-08       Impact factor: 1.990

5.  Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study.

Authors:  George J Shaw; Jason M Meunier; Christopher J Lindsell; Arthur M Pancioli; Christy K Holland
Journal:  Thromb Res       Date:  2010-09-01       Impact factor: 3.944

6.  Long-term stability of recombinant tissue plasminogen activator at -80 C.

Authors:  George J Shaw; Matthew Sperling; Jason M Meunier
Journal:  BMC Res Notes       Date:  2009-06-30

7.  Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".

Authors:  Jason M Meunier; Evan Wenker; Christopher J Lindsell; George J Shaw
Journal:  Acad Emerg Med       Date:  2013-05       Impact factor: 3.451

8.  Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots.

Authors:  Jason M Meunier; Christy K Holland; Arthur M Pancioli; Christopher J Lindsell; George J Shaw
Journal:  Thromb Res       Date:  2008-07-10       Impact factor: 3.944

9.  Tissue plasminogen activator concentration dependence of 120 kHz ultrasound-enhanced thrombolysis.

Authors:  George J Shaw; Jason M Meunier; Christopher J Lindsell; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2008-05-12       Impact factor: 2.998

10.  Temperature affects thrombolytic efficacy using rt-PA and eptifibatide, an in vitro study.

Authors:  Jason M Meunier; Wan-Tsu W Chang; Brent Bluett; Evan Wenker; Christopher J Lindsell; George J Shaw
Journal:  Ther Hypothermia Temp Manag       Date:  2012-09       Impact factor: 1.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.